抗氧化剂与血管扩张剂对人工耳蜗植入患者安全性和残余听力保护的随机安慰剂对照临床试验
结果显示ACEMg组500Hz听力损失较安慰剂组调整后减少8.01 dB,安全性良好,但试验因药物供应管理问题提前终止。
要点
- ACEMg(维生素A、C、E+镁)围手术期口服可能保护CI患者残余听力。
- 调整基线残余听力、电极长度和术者因素后,ACEMg组500Hz听力损失减少8.01 dB。
- ACEMg总体耐受良好,不良事件频率低于安慰剂组。
核心结论
- 首次在CI患者中评估药物对残余听力影响的临床试验,提示围手术期口服ACEMg安全且可能保护残余听力。
研究设计与样本
- ACEMg片剂或安慰剂分别于术前2天至术后3个月给药。
主要发现
- 意向性治疗人群25例ACEMg、24例安慰剂;首次调机后3个月500Hz平均听力损失为30.21 dB(±15.84,安慰剂)或26.00 dB(±17.56,ACEMg)。
- 调整基线残余听力、计划电极长度和术者因素后,ACEMg组听力损失较安慰剂组减少8.01 dB。
- 安全性分析显示ACEMg总体耐受良好,不良事件频率低于安慰剂水平。
临床怎么用
- 围手术期口服ACEMg可能作为CI患者残余听力保护的一种安全辅助策略,但需进一步验证。
局限性
- 试验因一合作方药物供应管理问题未达到招募目标即提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard therapy for patients suffering from sensorineural hearing loss is cochlear implantation. The insertion of the electrode array into the cochlea, with potential mechanical trauma and the presence of this foreign body inside the cochlea, may lead to free radical formation and reduced blood perfusion of the cochlea which can result in a loss of residual hearing. Studies have suggested that a particular combination of the antioxidants vitamins A, C and E as well as the vasodilator magnesium (together: ACEMg) may protect the residual hearing. METHODS: The potential protective effect of ACEMg on residual hearing preservation in cochlear implant (CI) patients was investigated in a single-centre, randomized, placebo-controlled, double-blind phase II clinical trial. CI candidates with some residual hearing in low frequencies receiving MED-EL implants of different FLEX electrode array lengths were treated with ACEMg tablets or placebo respectively 2 days preoperatively and up to 3 months postoperatively. The study objective was to demonstrate that ACEMg is more efficacious than placebo in preserving residual hearing during cochlear implantation by comparing the hearing loss (change in hearing thresholds at 500 Hz from baseline) 3 months after the first fitting between the two treatment groups and to investigate the treatments' safety. RESULTS: Fifty-one patients were included in the study, which had to be terminated before the recruitment goal was reached because of IMP-resupply mismanagement of one partner. In the intention-to-treat population, 25 patients were treated with ACEMg and 24 patients with placebo. The mean hearing loss at 500 Hz was (± 15.84) 30.21 dB (placebo) or (± 17.56) 26.00 dB (ACEMg) 3 months after the initial fitting. Adjusting the postoperative hearing loss for the baseline residual hearing, planned electrode length and surgeon results in 8.01 dB reduced hearing loss in ACEMg-treated patients compared to placebo-treated ones. The safety analysis revealed that ACEMg was generally well-tolerated with adverse event frequencies below the placebo level. CONCLUSION: This is the first clinical trial investigating a drug effect on residual hearing in CI patients. These first-in-man data may suggest that a perioperative oral administration of ACEMg is safe and may provide protection of residual hearing in CI patients. TRIAL REGISTRATION: EU Clinical Trial Register No. 2012-005002-22 . Registered on 6 December 2013. FUNDING: European Commission FP7-HEALTH-2012-INNOVATION-2.
引用
- Scheper V, Schmidtheisler M, Lasch F, et al. Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients. Trials. 2020. PMID: 32665006. doi:10.1186/s13063-020-04522-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。